Science is getting better at re-engineering micro-organisms for all kinds of uses, from better medical treatments to more durable materials. But there are still hurdles to overcome, including scaling the process. Boston-based Ginkgo Bioworks was one of the first billion-dollar companies in the synthetic biology space. The NYSE-listed company uses machine learning and automation to coax biology to work at industrial scale. COO Reshma Shetty talks to Azeem Azhar about the company’s technology, business model, and how big she thinks synthetic biology could become. @Azeem @exponentialview @reshmapshetty Further resources: The Bio Revolution: Innovations transforming economies, societies, and our lives – McKinsey, May 2020 Engineering Biology: The Next Frontier – Exponential View Podcast ft. Vijay Pande, June 2020 The Next Trillion-Dollar Market – Exponential View Podcast ft. Deep Nishar, April 2020 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Azeem Azhar's Exponential View
Transcribed and ready to explore now
The method of invention, AI's new clock speed and why capital markets are confused
05 Dec 2025
Azeem Azhar's Exponential View
Why the AI productivity gains haven’t arrived - yet
21 Nov 2025
Azeem Azhar's Exponential View
Where did all the entry-level jobs go? (With Revelio CEO Ben Zweig)
14 Nov 2025
Azeem Azhar's Exponential View
The demand for infinite compute
07 Nov 2025
Azeem Azhar's Exponential View
Inside the US–China decoupling: What’s really at stake (AI, rare earths, Taiwan, trade)
23 Oct 2025
Azeem Azhar's Exponential View
Inside the collapse of the internet economy (and what comes next)
08 Oct 2025
Azeem Azhar's Exponential View